The ability to peer into the genetic blueprint of an embryo before life has even begun represents one of the most profound shifts in modern medicine. Reproductive genomics—the application of advanced genetic analysis to fertility and pregnancy—is rapidly transforming how we understand conception, treat infertility, and shape the health of future generations. From whole-genome sequencing of embryos to artificial intelligence models that predict disease risk, the field is moving beyond simply helping people conceive toward helping them conceive healthier children.
This explores how genetic science is revolutionizing fertility treatment, what these technologies mean for patients and clinicians, and the ethical questions they raise.
What Is Reproductive Genomics?
Reproductive genomics is the application of high-throughput genetic analysis technologies—including whole-genome sequencing, transcriptomics, and epigenomics—to understand and improve human fertility, embryo development, and pregnancy outcomes. It encompasses everything from identifying genetic causes of infertility to screening embryos for hereditary diseases before implantation.
This field sits at the intersection of reproductive medicine and molecular genetics, using tools like DNA sequencing, bioinformatics, and increasingly artificial intelligence to decode the genetic factors that influence reproduction. The broader term “reproductomics” has emerged to describe the integration of multiple omics technologies—genomics, transcriptomics, proteomics, and metabolomics—for comprehensive reproductive health analysis.
How Genomics Is Changing IVF Treatment
From Aneuploidy Screening to Whole-Genome Sequencing
For over a decade, preimplantation genetic testing for aneuploidy (PGT-A) has been the standard approach for screening embryos created through IVF. This technology detects large chromosomal abnormalities—missing or extra chromosomes that typically prevent implantation or lead to miscarriage. The resolution of conventional PGT-A is limited to detecting abnormalities larger than 5 to 10 million base pairs.
Today, the field is shifting toward whole-genome sequencing (PGT-WGS), which analyzes all 3.2 billion base pairs of an embryo’s DNA. This comprehensive approach can detect:
- Inherited and de novo pathogenic mutations
- Small structural variations invisible to traditional PGT-A
- Single-gene disorders even without prior family history
- Copy number variations affecting development
The Implantation Gap: Why Euploid Embryos Fail
A critical driver of this technological shift is a persistent clinical puzzle: approximately 50% of embryos classified as chromosomally normal (euploid) fail to implant, and an additional 10% end in miscarriage . Dr. Antonio Capalbo, Scientific Director at Juno, notes that these failures may stem from lethal gene mutations—particularly those arising spontaneously in germ cells—that current technologies cannot detect.
Whole-genome sequencing offers a potential solution by identifying these hidden genetic abnormalities. Early studies suggest that comprehensive genome analysis can better predict implantation potential and reduce the uncertainty that currently plagues IVF outcomes.
AI and Genetic Optimization
The integration of artificial intelligence with genomic analysis represents another frontier. In October 2025, Nucleus Genomics launched Origin, a family of open-weight AI models trained on millions of individuals to predict health and longevity outcomes from embryonic DNA. According to the company, analyzing just five embryos can achieve greater than 50% risk reduction for common age-related conditions including Alzheimer’s disease, diabetes, and certain cancers .
Genetic Screening in Embryos: PGT and Precision Fertility
The Hierarchy of Genetic Testing
Contemporary embryo testing exists on a continuum rather than as a single test. The American Society for Reproductive Medicine (ASRM) describes a hierarchical approach to genomic testing in IVF :
- Level 1: Euploidy Assessment (PGT-A)
Screens for major chromosomal abnormalities. Provides value by accelerating time to conception, potentially lowering miscarriage rates, and reducing transfers of non-viable embryos.
- Level 2: PGT-WGS for Severe Pathogenic Mutations
Comprehensive analysis identifying monogenic disorders, structural aberrations, and tandem repeats that cause serious disease.
- Level 3: Polygenic Risk Screening with Family History
Evaluates cumulative genetic risk for complex conditions like heart disease and diabetes, guided by familial patterns.
- Level 4: Advanced Polygenic Screening
Incorporates variants of unknown significance and algorithmic risk predictions—approaches requiring careful counseling due to interpretive uncertainty.
Monogenic vs. Polygenic Conditions
Approximately 4% of people worldwide have a disease caused by a single genetic mutation. For these monogenic conditions—including cystic fibrosis, Huntington’s disease, and sickle cell anemia—embryo screening can effectively eliminate transmission to offspring.
Polygenic conditions, by contrast, result from the cumulative effect of dozens or hundreds of genetic variants. For these diseases—which include type 2 diabetes, coronary artery disease, and many psychiatric conditions—embryo screening can reduce but not eliminate risk. Orchid CEO Noor Siddiqui reports that with five embryos, couples can achieve 30–80% risk reduction for polygenic conditions depending on parental risk profiles.
Reproductive Genomics and Infertility Diagnosis
Uncovering Genetic Causes of Infertility
Before genomics, many cases of unexplained infertility remained truly mysterious. Today, genetic analysis is identifying specific molecular causes for conditions that previously had no clear etiology.
- Polycystic Ovary Syndrome (PCOS): Reproductomics studies have identified dysregulated microRNAs that serve as potential biomarkers for PCOS, offering new diagnostic and therapeutic targets. MicroRNA-409, for example, has been shown to affect ovarian function and insulin resistance in PCOS patients.
- Premature Ovarian Insufficiency (POI): Research using reproductomics tools has identified genetic markers associated with POI, while emerging therapies using mesenchymal stem cell-derived extracellular vesicles show promise for restoring ovarian function.
- Endometriosis: Genome-wide association studies (GWAS) have revealed remarkable consistency in genetic markers across populations, with meta-analyses confirming multiple susceptibility loci . Text mining of nearly 20,000 PubMed articles has identified over 1,500 endometriosis-associated genes, 121 of which show significant biological pathway enrichment.
Male Infertility Genetics
Genomic analysis is equally transformative for male infertility. Single-cell sequencing techniques now enable analysis of gene expression patterns in individual sperm cells, revealing defects in spermatogenesis that were previously undetectable. These technologies are identifying specific genetic abnormalities that impair sperm function, enabling targeted rather than empirical treatment approaches.
The Role of DNA Testing in Pregnancy Outcomes
Prenatal Genomics: From Screening to Prediction
The application of genomics extends beyond embryo selection to pregnancy management. Whole-genome sequencing of fetal DNA—either from chorionic villus sampling, amniocentesis, or increasingly from cell-free fetal DNA in maternal blood—provides increasingly detailed information about pregnancy outcomes.
Traditional prenatal screening focused on a handful of chromosomal abnormalities. Genomic approaches can now detect hundreds of genetic conditions, enabling:
- Early identification of treatable congenital disorders
- Informed preparation for delivery at specialized centers
- Anticipatory guidance for parents of affected children
Predicting Pregnancy Complications
Emerging research suggests that genomic analysis of both parents and embryos may predict pregnancy complications. Hypoxia-regulated genes, for example, have been identified as playing significant roles in conditions like preeclampsia and intrauterine growth restriction . By identifying embryos with genetic variants affecting placental development, clinicians may eventually select embryos with lower risk of these complications.
Ethical Issues in Reproductive Genomics
The Eugenic Concerns
The ability to select embryos based on genetic characteristics raises profound ethical questions. Critics argue that embryo screening for non-medical traits or even for disease risk reduction represents a form of eugenics—the selection of “desirable” genetic characteristics and elimination of those deemed undesirable.
The Center for Genetics and Society notes that preimplantation genetic diagnosis is promoted as a technology that could eliminate inherited diseases, boost birth rates, and reduce multiple births—but also represents a fundamental shift in how humans approach reproduction.
Access and Inequality
Current genomic technologies remain expensive. Whole-genome sequencing of embryos costs several thousand dollars per embryo, placing these services out of reach for many patients. This creates a concerning dynamic where affluent families can reduce genetic disease risk while lower-income families cannot, potentially exacerbating existing health disparities.
As ASRM’s Technology Committee notes, “exercising economic privilege in this manner can lead to discrimination and exacerbate social inequalities, as access to genetic trait selecting becomes limited to those who can afford it, furthering socio-economic disparities”.
The Question of Designer Babies
Perhaps the most contentious issue is whether parents will use these technologies to select for non-medical traits—intelligence, physical appearance, athletic ability. While such selection remains technically challenging and of uncertain effectiveness, the trajectory of the technology raises legitimate concerns.
ASRM authors caution that “parents seeking certain traits such as high intelligence, physical appearance traits or athletic ability may lead to immense pressure on children, unrealistic standards, emotional and mental harm that may actually facilitate development of mental diseases”.
Transparency and Open Science
In response to ethical concerns, some companies are embracing transparency. Nucleus Genomics has open-weighted its AI models, allowing independent researchers to scrutinize and build upon its technology. According to CEO Kian Sadeghi, “Too much of genetic optimization has been shrouded in secrecy. We reject that”.
The Future of Personalized Fertility Medicine
In-Vitro Gametogenesis
The most radical frontier in reproductive genomics is the creation of eggs and sperm from skin cells—a technology called in-vitro gametogenesis (IVG). Researchers at Oregon Health & Science University have been working to adapt techniques that succeeded in mice to human cells, though progress has been slower than anticipated.
In 2022, the OHSU team reported the birth of healthy mouse pups from eggs created from adult skin cell DNA. However, when attempting the technique with human cells, they encountered significant obstacles. The resulting human eggs had random chromosome distributions rather than the precise 23-chromosome complement required for healthy development. None of the 82 eggs fertilized in their experiments had the correct number of chromosomes.
Shoukhrat Mitalipov, who led the research, remains optimistic: “We will figure it out. We know it can be done.” He estimates that clinical applications remain at least a decade away.
If successful, IVG could transform fertility treatment by:
- Enabling women with diminished ovarian reserve to have genetically related children
- Allowing same-sex couples to have children genetically related to both parents
- Potentially eliminating age-related fertility decline
Gene Editing in Reproductive Medicine
CRISPR and other gene-editing technologies offer the possibility of correcting genetic abnormalities before implantation rather than simply selecting against affected embryos. However, this approach remains highly controversial and is not currently approved for clinical use in human reproduction.
As Dr. Lawrence Werlin of HRC Fertility notes, CRISPR applications “are being done now on an experimental basis” but remain unapproved for human use . The primary concern is off-target effects—unintended genetic changes that could be passed to future generations.
Regulatory Landscape
The regulatory environment for reproductive genomics varies significantly by jurisdiction. In the United States, no federal law completely bans human cloning, though some states prohibit it. A spending bill rider currently prevents the FDA from considering clinical trials involving genetically manipulated embryos.
Internationally, countries like Japan have begun explicitly allowing research using stem-cell derived gametes, suggesting increasing openness to these technologies. Amander Clark, a developmental biologist at UCLA, emphasizes that “public engagement in reproductive technologies is important now more than ever”.
Benefits and Risks of Genetic-Based Fertility Treatment
Documented Benefits
- Reduced miscarriage risk: By avoiding transfer of aneuploid embryos, patients can significantly lower miscarriage rates
- Prevention of serious genetic diseases: Monogenic disorders can be nearly completely eliminated through embryo selection
- Accelerated time to pregnancy: Avoiding transfer of non-viable embryos reduces the number of unsuccessful cycles
- Reduced psychological burden: Identifying aneuploid embryos helps patients understand that implantation failure is not their fault
Emerging Benefits
- Polygenic disease risk reduction: Embryo selection can reduce risk for common complex diseases by 30–80% depending on parental risk profiles
- Improved implantation prediction: Whole-genome sequencing may identify embryos with higher developmental potential
- Personalized treatment protocols: Genetic insights enable tailored stimulation protocols based on individual genetic profiles
Recognized Risks and Limitations
- Interpretive uncertainty: Many genetic variants have unknown significance; predicting disease risk remains imperfect
- False reassurance: A “normal” genetic screen does not guarantee a healthy child
- Cost and access: Technologies remain expensive, creating inequities
- Incidental findings: Whole-genome sequencing may reveal unexpected information about parental genetics or family relationships
- Technical limitations: Current techniques cannot guarantee correct chromosome distribution, as demonstrated by IVG research
Unknown Risks
- Long-term outcomes: The health of children born following extensive genetic manipulation remains unknown
- Multigenerational effects: Genetic interventions could have unanticipated effects in future generations
- Psychological impact: Knowledge of genetic risk factors may create anxiety for children and parents
Frequently Asked Questions
Is reproductive genomics used in IVF?
Yes, reproductive genomics is increasingly integrated into IVF practice. Preimplantation genetic testing (PGT) is widely used to screen embryos for chromosomal abnormalities and single-gene disorders. More advanced techniques like whole-genome sequencing are becoming available to provide comprehensive genetic analysis before embryo transfer.
Can genetics explain infertility?
Genetics can explain many cases of previously “unexplained” infertility. Research has identified genetic causes for conditions including polycystic ovary syndrome, premature ovarian insufficiency, endometriosis, and male factor infertility. Reproductomics studies continue to uncover new genetic markers and molecular mechanisms underlying fertility disorders.
What is embryo genetic testing?
Embryo genetic testing involves analyzing the DNA of embryos created through IVF before selecting which to transfer. Tests range from PGT-A (screening for major chromosomal abnormalities) to PGT-M (testing for specific inherited single-gene disorders) to whole-genome sequencing (comprehensive analysis of all genetic variations). These tests help identify embryos with the highest likelihood of successful pregnancy and lowest risk of genetic disease.
Is reproductive genomics safe?
Current reproductive genomics techniques like embryo biopsy and genetic testing are generally considered safe, with no demonstrated increased risk of birth defects or developmental problems. However, some advanced techniques—particularly gene editing—remain experimental and are not approved for clinical use. Long-term outcomes data continues to accumulate, and patients should discuss risks with their fertility specialist.
How is genomics changing fertility treatment?
Genomics is transforming fertility treatment from an empirical process to a precision medicine approach. Rather than relying on trial and error, clinicians can now identify specific genetic causes of infertility, select embryos with the highest implantation potential, screen for hundreds of genetic conditions before pregnancy, and potentially reduce lifelong disease risk for offspring. The integration of AI and whole-genome sequencing promises to further improve outcomes.
The Dawn of Predictive Reproductive Medicine
Reproductive genomics stands at a transformative moment. The convergence of falling sequencing costs, advances in AI, and deeper understanding of genetic mechanisms is shifting fertility care from treating infertility to optimizing reproductive outcomes.
Over the next decade, we can expect several developments to reshape the field:
- First, whole-genome sequencing will likely become the standard for embryo evaluation, replacing more limited screening approaches. As Dr. Capalbo predicts, “WGS is the next frontier of PGT. It allows us to offer patients a full genetic assessment, without relying on family history or prior suspicion”.
- Second, polygenic risk scores will become increasingly sophisticated, enabling more accurate prediction of complex disease risk. With AI models trained on increasingly diverse populations, the predictive power of these tools will improve substantially.
- Third, the development of in-vitro gametogenesis, if successful, will fundamentally alter the possibilities for family building—enabling same-sex couples to have genetically related children and eliminating the age-related decline in female fertility.
Yet these advances come with profound responsibilities. The ethical challenges—ensuring equitable access, preventing discriminatory applications, maintaining transparency, and respecting the autonomy of future children—will require ongoing engagement from clinicians, patients, policymakers, and society at large.
As Amander Clark observes, “Restorative reproductive medicine is unlikely to help women with low ovarian reserve, or gamete scarcity, and IVF is reaching the limits of what it can do to help these people. A transformative leap in reproductive technologies is needed to overcome these forms of infertility. How society gets there will benefit from robust public engagement combined with transparency from the scientists on safety and risks”.
Reproductive genomics offers that transformative leap. Whether it leads to a future of healthier children and more successful fertility treatment—or one of deepened inequality and ethical overreach—depends on the choices we make today.